drugset / Trial / NCT02296762

Bioavailability Study of Sirolimus Tablets 2 mg Under Fed Condition

NCT02296762

Phase 1 Completed 36 enrolled Dr. Reddy's Laboratories Limited
RandomizedCrossoverOpen-labelTreatment

Summary

This study is to assess the Sirolimus Tablets 2 mg of Dr. Reddy's Laboratories Limited, India and Rapamune® (Sirolimus) tablets 2 mg of Wyeth Laboratories, Philadelphia in healthy, adult,human subjects under Fed conditions.

Timeline

Start
2010-02
Primary completion
2010-02
Completion
2010-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Sirolimus Small molecule 2 mg Oral

Indications

No indication recorded.